雷尼替丁——一种新型H2受体拮抗剂。
Ranitidine--a new H2-receptor antagonist.
作者信息
Woodings E P, Dixon G T, Harrison C, Carey P, Richards D A
出版信息
Gut. 1980 Mar;21(3):187-91. doi: 10.1136/gut.21.3.187.
Abstract
The pharmacokinetics and gastric antisecretory effects of a new histamine H2-receptor antagonist, ranitidine hydrochloride, have been investigated in healthy subjects. In the pharmacokinetic study six subjects received 20 mg, 40 mg, and 80 mg ranitidine, both orally and intravenously. Plasma levels of ranitidine were dose-related and in most subjects after oral drug the concentration time curve was bimodal. The estimated elimination half-life was 140 minutes and the bioavailability of the oral drug was about 50%. Five subjects received bolus intravenous injections of ranitidine 20 mg, 40 mg, and 80 mg during continuous gastric stimulation with pentagastrin. There was a dose-related reduction in acid output (P less than 0.05).
摘要
已在健康受试者中研究了一种新型组胺H2受体拮抗剂盐酸雷尼替丁的药代动力学和胃抗分泌作用。在药代动力学研究中，6名受试者口服和静脉注射了20mg、40mg和80mg雷尼替丁。雷尼替丁的血浆水平与剂量相关，在大多数口服药物的受试者中，浓度-时间曲线呈双峰。估计消除半衰期为140分钟，口服药物的生物利用度约为50%。5名受试者在五肽胃泌素持续刺激胃的过程中静脉注射了20mg、40mg和80mg雷尼替丁推注。胃酸分泌量呈剂量相关减少（P<0.05）。
相似文献
1
Ranitidine--a new H2-receptor antagonist.
Gut. 1980 Mar;21(3):187-91. doi: 10.1136/gut.21.3.187.
2
[Effects of ranitidine, a new histamine H2-receptor antagonist, on secretagogue-stimulated gastric secretion in Heidenhain pouch dogs (author's transl)].
Nihon Yakurigaku Zasshi. 1981 Dec;78(6):539-47.
3
Pharmacokinetic and gastric secretory studies of ranitidine in man.
Scand J Gastroenterol Suppl. 1981 Jun;69:11-7.
4
Inhibition of pentagastrin-stimulated and nocturnal gastric secretion by ranitidine. A new H2-receptor antagonist.
Lancet. 1979 Mar 31;1(8118):690-2. doi: 10.1016/s0140-6736(79)91146-2.
5
The new histamine H2-receptor antagonist ranitidine. Duration of action.
Scand J Gastroenterol Suppl. 1981 Jun;69:39-43.
6
Furan H2-antagonist ranitidine inhibits pentagastrin-stimulated gastric secretion stronger than cimetidine.
Gastroenterology. 1980 Dec;79(6):1267-71.
7
Inhibition of gastric acid secretion in the dog by the H2-receptor antagonists, ranitidine, cimetidine, and metiamide.
Gut. 1980 May;21(5):408-12. doi: 10.1136/gut.21.5.408.
8
Inhibition of gastric secretion in man with a new H2-receptor antagonist, ranitidine.
Scand J Gastroenterol. 1980;15(2):249-51. doi: 10.3109/00365528009181464.
9
Kinetics and duration of action of ranitidine on gastric secretion and its effect on pancreatic secretion in duodenal ulcer patients.
Scand J Gastroenterol Suppl. 1981 Jun;69:91-9.
10
[Effects of ranitidine, a new histamine H2-receptor antagonist, on secretagogue-stimulated gastric secretion in rats: comparison with cimetidine (author's transl)].
Nihon Yakurigaku Zasshi. 1981 Aug;78(2):57-62.
引用本文的文献
1
Sir David Jack: an extraordinary drug discoverer and developer.
Br J Clin Pharmacol. 2013 May;75(5):1213-8. doi: 10.1111/j.1365-2125.2012.04467.x.
2
Multiple peaking phenomena in pharmacokinetic disposition.
Clin Pharmacokinet. 2010 Jun;49(6):351-77. doi: 10.2165/11319320-000000000-00000.
3
Effect of pancreatico-biliary secretions and GI transit time on the absorption and pharmacokinetic profile of ranitidine in humans.
Pharm Res. 1998 Aug;15(8):1281-5. doi: 10.1023/a:1011908412058.
4
Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth.
Br J Cancer. 1996 Apr;73(7):872-6. doi: 10.1038/bjc.1996.155.
5
Regional gastrointestinal absorption of ranitidine in the rat.
Pharm Res. 1995 Sep;12(9):1311-5. doi: 10.1023/a:1016269522828.
6
Clinical pharmacokinetics of ranitidine.
Clin Pharmacokinet. 1984 May-Jun;9(3):211-21. doi: 10.2165/00003088-198409030-00003.
7
Pharmacokinetics of ranitidine in patients with chronic renal failure.
Eur J Clin Pharmacol. 1983;25(3):347-51. doi: 10.1007/BF01037946.
8
The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders.
Eur J Clin Pharmacol. 1983;24(4):441-7. doi: 10.1007/BF00609883.
9
Effect of ranitidine on the steady state pharmacokinetics of diazepam.
Eur J Clin Pharmacol. 1983;24(3):357-60. doi: 10.1007/BF00610055.
10
Cimetidine-resistant Zollinger-Ellison syndrome: successful management with ranitidine.
Can Med Assoc J. 1983 Aug 1;129(3):256-8.
本文引用的文献
1
Positioning of subject and of nasogastric tube during a gastric secretion study.
Br Med J. 1970 Feb 21;1(5694):458-60. doi: 10.1136/bmj.1.5694.458.
2
Response to pentagastrin in Man. IV. Dose-response characteristics.
Acta Hepatogastroenterol (Stuttg). 1976 Apr;23(2):124-30.
3
The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine--studies in patients with peptic ulcer disease.
Br J Clin Pharmacol. 1979 Jan;7(1):23-31. doi: 10.1111/j.1365-2125.1979.tb00892.x.
4
Inhibition of pentagastrin-stimulated and nocturnal gastric secretion by ranitidine. A new H2-receptor antagonist.
Lancet. 1979 Mar 31;1(8118):690-2. doi: 10.1016/s0140-6736(79)91146-2.
5
Gastric inhibitory action of H2-antagonists ranitidine and cimetidine.
Lancet. 1979 Feb 10;1(8111):320. doi: 10.1016/s0140-6736(79)90728-1.
6
Ranitidine (AH 19065): a new potent, selective histamine H2-receptor antagonist [proceedings].
Br J Pharmacol. 1979 Jul;66(3):464P.
7
Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man.
Br J Clin Pharmacol. 1975 Dec;2(6):481-6. doi: 10.1111/j.1365-2125.1975.tb00564.x.
Zotero 插件